Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-CM Pleiotropic Factor for Residual Burn Wounds
NCT04235296Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Biologic, CFT (Cell-free therapy)
- Countries
- 1
01
Overview
Phase 1, randomised trial of mesenchymal stem cell-derived pleiotropic factor in burn injury (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Wound healing rate at 2 months. Status: unknown.
02
Drugs
mesenchymal stem cell-derived pleiotropic factor
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT04235296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235296.